-$0.49 Earnings Per Share Expected for Ovid Therapeutics Inc (NASDAQ:OVID) This Quarter

Equities analysts expect that Ovid Therapeutics Inc (NASDAQ:OVID) will post ($0.49) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Ovid Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.51). Ovid Therapeutics reported earnings per share of ($0.53) in the same quarter last year, which suggests a positive year-over-year growth rate of 7.5%. The business is expected to issue its next quarterly earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Ovid Therapeutics will report full year earnings of ($1.84) per share for the current fiscal year, with EPS estimates ranging from ($2.15) to ($1.52). For the next year, analysts anticipate that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($4.55) to ($0.53). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ovid Therapeutics.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Several research analysts have weighed in on the company. Zacks Investment Research lowered Ovid Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Cowen reaffirmed a “buy” rating on shares of Ovid Therapeutics in a research report on Sunday, May 12th. ValuEngine lowered Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. LADENBURG THALM/SH SH reissued a “buy” rating and set a $27.00 price objective on shares of Ovid Therapeutics in a report on Thursday, May 16th. Finally, Piper Jaffray Companies lowered their price objective on Ovid Therapeutics to $14.00 and set an “overweight” rating on the stock in a report on Sunday, March 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $12.85.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in Ovid Therapeutics during the 1st quarter valued at approximately $31,000. Rhumbline Advisers boosted its stake in Ovid Therapeutics by 47.2% during the 4th quarter. Rhumbline Advisers now owns 16,551 shares of the company’s stock valued at $40,000 after purchasing an additional 5,310 shares during the period. SG Americas Securities LLC bought a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $46,000. Oxford Asset Management LLP boosted its stake in Ovid Therapeutics by 160.2% during the 1st quarter. Oxford Asset Management LLP now owns 61,066 shares of the company’s stock valued at $108,000 after purchasing an additional 37,599 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $114,000. 31.73% of the stock is currently owned by institutional investors and hedge funds.

Shares of OVID stock opened at $1.77 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.78 and a current ratio of 7.78. Ovid Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $11.45.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Recommended Story: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on Ovid Therapeutics (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.